Stocklytics Platform
Asset logo for symbol IBRX
ImmunityBio
IBRX62
$2.62arrow_drop_down1.68%-$0.04
Penny Stock
Asset logo for symbol IBRX
IBRX62

$2.62

arrow_drop_down1.68%

Performance History

Chart placeholder
Key Stats
Open$2.66
Prev. Close$2.67
EPS-0.90
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.91B
PE Ratio-
LOWHIGH
Day Range2.61
2.78
52 Week Range1.25
10.53
Ratios
Revenue-
EBITDA Margin %-
EPS-0.90

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About ImmunityBio (IBRX)

ImmunityBio, Inc. (IBRX) is a biotechnology company that focuses on developing and commercializing immunotherapy products for the treatment of various diseases. The company's mission is to provide effective and affordable treatments that harness the power of the immune system to fight cancer and other diseases.
As of the most recent trading day, the stock price of ImmunityBio, Inc. (IBRX) was $10.25. Over the past year, the stock has traded in a range of $5.12 to $19.35. The current market capitalization of ImmunityBio, Inc. is $1.5 billion.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Richard Gerald Adcock
Headquarters
San Diego
Employees
683
Exchange
NASDAQ
add ImmunityBio to watchlist

Keep an eye on ImmunityBio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is ImmunityBio's (IBRX) price per share?

The current price per share for ImmunityBio (IBRX) is $2.62. The stock has seen a price change of -$0.04 recently, indicating a -1.69% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for ImmunityBio (IBRX)?

For ImmunityBio (IBRX), the 52-week high is $10.53, which is 301.91% from the current price. The 52-week low is $1.25, the current price is 109.6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is ImmunityBio (IBRX) a growth stock?

ImmunityBio (IBRX) has shown an average price growth of -4.38% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ImmunityBio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is ImmunityBio (IBRX) stock price performance year to date (YTD)?

As of the latest data, ImmunityBio (IBRX) has a year-to-date price change of -50%. Over the past month, the stock has experienced a price change of -46.26%. Over the last three months, the change has been -25.57%. Over the past six months, the figure is -59.69%.
help

Is ImmunityBio (IBRX) a profitable company?

ImmunityBio (IBRX) has a net income of -$583.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.31K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $622K. Operating income is noted at -$362.25M. Furthermore, the EBITDA is -$341.3M.
help

What is the market capitalization of ImmunityBio (IBRX)?

ImmunityBio (IBRX) has a market capitalization of $1.91B. The average daily trading volume is 2.64, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level